Immune cell kinetics and antibody response in COVID ‐19 patients with low‐count monoclonal B‐cell lymphocytosis
American Journal of Hematology · 2023
DOI: 10.1002/ajh.27119 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Hematology, 2023. Verfasst von Guillermo Oliva-Ariza und 32 weiteren Autor:innen. Beteiligte Einrichtung: Translational and Clinical Research Program, Cancer Research Center (IBMCC, CSIC - University of Salamanca); Cytometry Service, NUCLEUS, University o…. Hauptthemen laut MEDLINE: Lymphocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, COVID-19, Neoplasms, Plasma Cell. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Centro de Investigación Biomédica en Red de Cáncer, Consejería de Educación, Junta de Castilla y León, Instituto de Salud Carlos III.
Abstract (Originalsprache)
Low‐count monoclonal B‐cell lymphocytosis (MBL lo ) has been associated with an underlying immunodeficiency and has recently emerged as a new risk factor for severe COVID‐19. Here, we investigated the kinetics of immune cell and antibody responses in blood during COVID‐19 of MBL lo versus non‐MBL patients. For this study, we analyzed the kinetics of immune cells in blood of 336 COVID‐19 patients (74 MBL lo and 262 non‐MBL), who had not been vaccinated against SARS‐CoV‐2, over a period of 43 weeks since the onset of infection, using high‐sensitivity flow cytometry. Plasma levels of anti‐SARS‐CoV‐2 antibodies were measured in parallel by ELISA. Overall, early after the onset of symptoms, MBL lo COVID‐19 patients showed increased neutrophil, monocyte, and particularly, plasma cell (PC) counts, whereas eosinophil, dendritic cell, basophil, and lymphocyte counts were markedly decreased in blood of a variable percentage of samples, and with a tendency toward normal levels from week +5 of infection onward. Compared with non‐MBL patients, MBL lo COVID‐19 patients presented higher neutrophil counts, together with decreased pre‐GC B‐cell, dendritic cell, and innate‐like T‐cell counts. Higher PC levels, together with a delayed PC peak and greater plasma levels of anti‐SARS‐CoV‐2‐specific antibodies (at week +2 to week +4) were also observed in MBL lo patients. In summary, MBL lo COVID‐19 patients share immune profiles previously described for patients with severe SARS‐CoV‐2 infection, associated with a delayed but more pronounced PC and antibody humoral response once compared with non‐MBL patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Translational and Clinical Research Program, Cancer Research Center (IBMCC, CSIC - University of Salamanca); Cytometry Service, NUCLEUS, University of Salamanca (Universidad de Salamanca), Salamanca, Spain.
- Department of Medicine, University of Salamanca (Universidad de Salamanca), Salamanca, Spain.
- Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
- Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain.
- Department of Internal Medicine, University Hospital of Salamanca, Salamanca, Spain.
- Department of Infectious Diseases, University Hospital of Salamanca, Centro de Investigación de Enfermedades Tropicales de la Universidad de Salamanca (CIETUS), Salamanca, Spain.
ORCID-Profile: Guillermo Oliva-Ariza, Óscar González-López, Julia Almeida
Förderung
- Centro de Investigación Biomédica en Red de Cáncer
- Consejería de Educación, Junta de Castilla y León
- Instituto de Salud Carlos III
- Interreg
- Junta de Castilla y León
Zitieren
APA
Oliva-Ariza, G., Fuentes-Herrero, B., Lecrevisse, Q., Carbonell, C., Pérez-Pons, A., Torres-Valle, A., Pozo, J., Martín-Oterino, J. Á., González-López, Ó., López-Bernús, A., Bernal-Ribes, M., Belhassen-García, M., Pérez-Escurza, O., Pérez-Andrés, M., Vazquez, L., Hernández-Pérez, G., García Palomo, F. J., Leoz, P., Costa-Alba, P., …, & ECRIN-M3 Consortium (2023). Immune cell kinetics and antibody response in COVID ‐19 patients with low‐count monoclonal B‐cell lymphocytosis. American Journal of Hematology. https://doi.org/10.1002/ajh.27119
Vancouver
Oliva-Ariza G, Fuentes-Herrero B, Lecrevisse Q, Carbonell C, Pérez-Pons A, Torres-Valle A, et al. Immune cell kinetics and antibody response in COVID ‐19 patients with low‐count monoclonal B‐cell lymphocytosis. American Journal of Hematology. 2023. doi:10.1002/ajh.27119
BibTeX
@article{OlivaAriza2023,
author = {Oliva-Ariza, Guillermo and Fuentes-Herrero, Blanca and Lecrevisse, Quentin and Carbonell, Cristina and Pérez-Pons, Alba and Torres-Valle, Alba and Pozo, Julio and Martín-Oterino, José Ángel and González-López, Óscar and López-Bernús, Amparo and Bernal-Ribes, Marta and Belhassen-García, Moncef and Pérez-Escurza, Oihane and Pérez-Andrés, Martín and Vazquez, Lourdes and Hernández-Pérez, Guillermo and García Palomo, Francisco Javier and Leoz, Pilar and Costa-Alba, Pilar and Pérez-Losada, Elena and Yeguas, Ana and Santos Sánchez, Miryam and García-Blázquez, Marta and Morán-Plata, F Javier and Damasceno, Daniela and Botafogo, Vitor and Muñoz-García, Noemí and Fluxa, Rafael and van Dongen, Jacques J M and Marcos, Miguel and Almeida, Julia and Orfao, Alberto and ECRIN-M3 Consortium, ECRIN-M3 Consortium},
title = {Immune cell kinetics and antibody response in COVID ‐19 patients with low‐count monoclonal B‐cell lymphocytosis},
journal = {American Journal of Hematology},
year = {2023},
doi = {10.1002/ajh.27119}
}
EUVIMED